Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC
程序性死亡配体1肿瘤比例评分与一线帕博利珠单抗治疗非鳞状与鳞状非小细胞肺癌患者的总生存期
期刊:Journal of Thoracic Oncology
影响因子:20.8
doi:10.1016/j.jtho.2021.07.032
Doroshow, Deborah B; Wei, Wei; Gupta, Swati; Zugazagoitia, Jon; Robbins, Charles; Adamson, Blythe; Rimm, David L